Glenmark Pharmaceuticals Limited · NSE:GLENMARK
Glenmark Pharmaceuticals — 37th Annual J.P. Morgan Healthcare Conference 2019
24 slides from Glenmark Pharmaceuticals's conference presentation, Jan 8, 2019
Slide 1: Exchange filing cover letter for J.P. Morgan Healthcare Conference presentation
January 8, 2019 To, To, Dy. General Manager The Manager – Listing, Department of Corporate Services, The National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Bandra Kurla Complex, Fort, Mumbai – 400 001. Bandra (E), Mumbai – 400 051. Ref: Scrip Code: 53
Slide 2: Glenmark Pharmaceuticals Ltd. 37th Annual J.P. Morgan Healthcare Conference
Do not copy or distribute Glenmark Pharmaceuticals Ltd. 37th Annual J.P. Morgan Healthcare Conference January 2019
Slide 3: Disclaimer
Do not copy or distribute 2 Disclaimer These materials have been prepared by Glenmark Pharmaceuticals (“Glenmark” or the “Company”) solely for informational purposes, and are strictly confidential and may not be taken away, reproduced or redistributed to any other person. By attending this presentat
Slide 4: Glenmark is a research oriented, integrated global pharmaceutical company
Do not copy or distribute 3 Glenmark is a research oriented, integrated global pharmaceutical company Annual revenue of ~$1.5 bn in Commercial infrastructure in the FY19E with CAGR of ~12% over US, India, Europe, Russia and last 5 years other emerging markets Global manufacturing footprint EBITDA pr
Slide 5: Business overview
Do not copy or distribute 4 Business overview Glenmark Pharmaceuticals in 2019 Formulations – Generics, Branded Generics, OTC API Manufacturing Innovative Research & Marketing North India & Europe & and Development ARCIS America MEA LATAM Contribution 9% 32% 16% 9% 2% to Glenmark 30% • BGx: 90% • Ge
Slide 6: Business overview
Do not copy or distribute 5 Business overview Glenmark Pharmaceuticals in 2019 Formulations – Generics, Branded Generics, OTC API Manufacturing Innovative Research & Marketing North India & Europe & and Development ARCIS America MEA LATAM Contribution 9% 32% 16% 9% 2% to Glenmark 30% • BGx: 90% • Ge
Slide 7: API Business
Do not copy or distribute 6 API Business Business Today Strategic Priorities Target revenue growth of 15+% • $200+ mn* revenue with EBITDA margin of >30% and maintain profitability at current levels • One of the leading players in products such as Amiodarone, Lercanidipine, Atovaquone, Aprepitant an
Slide 8: Business overview
Do not copy or distribute 7 Business overview Glenmark Pharmaceuticals in 2019 Formulations – Generics, Branded Generics, OTC API Manufacturing Innovative Research & Marketing North India & Europe & and Development ARCIS America MEA LATAM Contribution 9% 32% 16% 9% 2% to Glenmark 30% • BGx: 90% • Ge
Slide 9: Formulation business – key growth drivers
Do not copy or distribute 8 Formulation business – key growth drivers Focus on select Rx therapeutic areas Build strong partnerships • Primary areas – Dermatology, Respiratory, Oncology across all markets • Secondary areas – Cardio-metabolic, CNS in select markets Launch global brands Strengthen com
Slide 10: North America
Do not copy or distribute 9 North America Business Today Strategic Priorities • ~$480 mn revenue with 5-year CAGR of 10% Will enter specialty respiratory • Ranked 15th* in terms of total prescriptions filled market with launch of RyaltrisTM by generic companies • 145 ANDAs approved, 50+ pending appr
Slide 11: India and MEA
Do not copy or distribute 10 India and MEA Business Today Strategic Priorities • Revenue of ~$450 mn with 5-year CAGR of 13% Launch innovative products through strategic partnerships • Has consistently grown faster than the overall market • 8 brands among the top 300 Brands in the Indian Establish l
Slide 12: Europe and LATAM
Do not copy or distribute 11 Europe and LATAM Business Today Strategic Priorities • Revenue of ~$235 mn with 5-year CAGR of 13% Expand presence in respiratory segment; e.g. Gx Seretide® DPI, • Key markets include the UK, Germany, Poland, Tiotropium DPI, RyaltrisTM Brazil and Mexico • Strong product
Slide 13: ARCIS
Do not copy or distribute 12 ARCIS Business Today Strategic Priorities • Revenue of ~$130 mn showing robust growth Life-cycle management for • Ranks 7th in the dermatology market and 4th in the products such as Momate Rhino expectorant market in Russia Advance® and Oflomil® • Strengthened presence i
Slide 14: Looking to build powerful brands through global launches – Ryaltris
Do not copy or distribute 13 Looking to build powerful brands through global launches – RyaltrisTM • Fixed dose nasal spray combination of mometasone furoate and olopatadine Expected launch in H1 CY19 in hydrochloride the US • First global specialty brand of Glenmark • NDA filed with the US FDA and
Slide 15: Looking to build powerful brands through global launches – GBR 310 and GSP 304
Do not copy or distribute 14 Looking to build powerful brands through global launches – GBR 310 and GSP 304 • GBR 310 is proposed biosimilar of Xolair® (omalizumab) Potential to become one of the first biosimilars of Xolair® • Xolair® sales of ~$1.7 bn in the US, and ~$0.9 bn in in the US ex-US mark
Slide 16: Business overview
Do not copy or distribute 15 Business overview Glenmark Pharmaceuticals in 2019 Formulations – Generics, Branded Generics, OTC API Manufacturing Innovative Research & Marketing North India & Europe & and Development ARCIS America MEA LATAM Contribution 9% 32% 16% 9% 2% to Glenmark 30% • BGx: 90% • G
Slide 17: Glenmark is one of the leading innovative R&D-focused companies from the emerging markets
Do not copy or distribute 16 Glenmark is one of the leading innovative R&D-focused companies from the emerging markets NEW BIOLOGICAL ENTITIES (NBE) RESEARCH • 160+ scientists based in Neuchatel, Switzerland • GMP certified biologics manufacturing facility CLINICAL NEW CHEMICAL ENTITIES (NCE) DEVELO
Slide 18: Innovative research pipeline
Do not copy or distribute 17 Innovative research pipeline Pre Therapy Molecule MoA/Class Potential Indication Phase 1 Phase 2a Phase 2b Phase 3 Approval Clinical - Atopic Dermatitis OX40 GBR 830 Antagonist - Systemic Lupus Immunology Erythematosus (SLE) - Ulcerative Colitis (UC) RORγt GRC 39815 - CO
Slide 19: Innovative research pipeline - Summary
Do not copy or distribute 18 Innovative research pipeline - Summary 2 clinical assets currently 5 clinical and 4 pre-clinical 3 immuno-oncology in Phase 2b, and one assets currently in bispecific antibodies from asset likely to enter Phase development the BEAT® platform 2b in FY20 All clinical asset
Slide 20: Strong focus on corporate social responsibility (CSR)
Do not copy or distribute 19 Strong focus on corporate social responsibility (CSR) • Glenmark listed in the Dow Jones Sustainability Emerging Markets Index 2018 – One among the two pharmaceutical companies to be listed in the DJSI Emerging Markets Index • Impact of CSR initiatives – 8,70,000+ lives
Slide 21: Projected revenue roadmap going forward – Moving up the value chain
Do not copy or distribute 20 Projected revenue roadmap going forward – Moving up the value chain Illustrative 2023 Onwards Anticipated launch of NME products 2019 – 2022 Anticipated launch of dermatology and respiratory specialty products Current Business Generics / branded generics 2016 2018 2019 2
Slide 22: Financial objectives
Do not copy or distribute 21 Financial objectives • Target consolidated revenue growth of 12-15% over the next 3-5 years • R&D expense to continue at 12-13% of revenue • Continue to focus on margin expansion • Ensure that business is free cash flow generating • Net debt to EBITDA ratio to progressiv
Slide 23: Summary: Glenmark Today and Glenmark in 2025
Do not copy or distribute 22 Summary Glenmark Today Glenmark in 2025 • Further scaling up the branded • Global pharmaceutical business generic business globally across generics, branded generics • Initiating launch of specialty and OTC dermatology and respiratory • Specialty business to ramp-up prod
Slide 24: Glenmark – A new way for a new world
G glenmar A new way for a new world
Glenmark Pharmaceuticals — 37th Annual J.P. Morgan Healthcare Conference 2019 on 6ix